Welcome to our dedicated page for PHIBRO ANIMAL HEALTH SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PHIBRO ANIMAL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PHIBRO ANIMAL HEALTH's regulatory disclosures and financial reporting.
Phibro Animal Health Corporation (PAHC) reporting person Larry Lee Miller, Chief Operating Officer, was granted 5,184 restricted stock units (RSUs) on 08/15/2025. After the grant, Mr. Miller beneficially owns 35,184 shares of Class A Common Stock. The RSUs are contingent rights to receive one share per RSU and vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to his continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing discloses a routine equity award to an executive with time-based vesting; no option exercises, sales, or derivative transactions are reported.
Judith Weinstein, Senior Vice President, General Counsel and Corporate Secretary of Phibro Animal Health Corp (PAHC), was granted 3,447 restricted stock units (RSUs) on 08/15/2025. Each RSU represents a contingent right to receive one share of Class A common stock and the reported ownership following the grant is 3,447 shares (direct). The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed and dated 08/19/2025.
David Glenn, Chief Financial Officer of Phibro Animal Health Corporation (PAHC), received a grant of restricted stock units (RSUs). The Form 4 reports an acquisition dated 08/15/2025 of 4,845 RSUs at a $0 price, bringing his total beneficial ownership to 34,845 shares of Class A Common Stock. The RSUs each represent a contingent right to one share and vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment. The filing was signed by an attorney-in-fact on 08/19/2025. The disclosure reflects a routine executive equity award with time-based vesting.
Jonathan Bendheim, a director of Phibro Animal Health Corp (PAHC), reported acquiring 3,268 restricted stock units (RSUs) on 08/15/2025. These RSUs are contingent rights to receive one share of Class A common stock each and were reported as acquired at a $0 price. Following the reported transaction, Mr. Bendheim beneficially owns 3,268 shares (direct). The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to his continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Daniel M. Bendheim, Executive Vice President, Corporate Strategy and a director of Phibro Animal Health Corporation (PAHC), reported a grant of 3,964 restricted stock units (RSUs) on 08/15/2025. The RSUs represent contingent rights to receive one share of Class A Common Stock per unit and were awarded at $0 purchase price. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Jack Bendheim, who is listed as a director, 10% owner and President and CEO of Phibro Animal Health Corp (PAHC), reported a non‑derivative acquisition on 08/15/2025 of 16,840 restricted stock units (RSUs). Each RSU represents a contingent right to one share of Class A common stock and was reported at a $0 price.
The filing shows 76,320 shares beneficially owned by the reporting person after the transaction. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment. The Form 4 was signed by an attorney‑in‑fact on behalf of Mr. Bendheim on 08/19/2025.
Insider grant of restricted stock units to a senior officer at Phibro Animal Health (PAHC). Lisa Ann Escudero, Senior Vice President, Human Resources, was awarded 2,152 restricted stock units (RSUs) on 08/15/2025. Each RSU represents the contingent right to receive one share of Class A Common Stock and was reported with a transaction code indicating a grant at $0. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, provided the reporting person remains employed through each vesting date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.
Anthony Andolino, Vice President Finance and Treasurer of Phibro Animal Health Corp (PAHC), received an award of 1,793 restricted stock units (RSUs) on 08/15/2025. Each RSU represents a contingent right to one share of Class A common stock and was granted at a $0 price. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Andolino on 08/19/2025.